What Novavax needs for success as it advances blockbuster vaccine candidates

As Novavax Inc. continues to push its flu and RSV vaccine candidates through clinical trials, the Gaithersburg biotech is inching closer to both finish lines, expecting new data within a few months. And, as Novavax (NASDAQ: NVAX) CEO Stanley Erck said on a Wednesday earnings call, “We are preparing for success.” The company is now three to four months away from reporting results for its two lead vaccine programs. For both — heavily watched vaccine candidate NanoFlu, completing phase 2 trials,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news